

## APPOINTMENT OF CELGENE VETERAN DR GEORGE MATCHAM AS NON-EXECUTIVE DIRECTOR

Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), a clinical stage cell therapy company, is pleased to announce Dr George Matcham has been appointed to the board as a Non-Executive Director.

Dr Matcham brings to Chimeric a wealth of experience in the biopharma sector, following an instrumental three decades with cell therapy giant Celgene Corporation. He joined Celgene in its infancy in 1988 when the company was a 30-person startup, retiring in 2018 with the company turning over \$15 billion annually and a staff of almost 9,000.

At Celgene, Dr Matcham championed the introduction of cellular immunotherapy and led the establishment of cell therapy and biologics technical development. Vital to the growth of cell therapy at Celgene, Dr Matcham held several senior positions, including Chief Operations Officer of Celgene Cellular Therapeutics and Senior Vice President of CAR T CMC Development, where he oversaw clinical supply.

He holds a Ph.D. in Biochemistry from Cardiff University, as well as a M.A from the prestigious Cambridge University.

In recent years, Dr Matcham has also served on the board and as an advisor at Instil Bio throughout its financing rounds and IPO.

“We have been focused on securing a world-class team in cell therapy for Chimeric Therapeutics, and appointing George to the board is another big step in that direction,” said Paul Hopper, Executive Chairman and Founder of Chimeric.

“He has a wealth of experience with a leader in the sector and his insights and contribution will be invaluable in what will be a significant period of growth for Chimeric.”

**Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.**

### ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing novel cell therapies to patients with cancer.

Chimeric believes that cellular therapies have the potential to cure cancer and that by combining their expertise in the development and commercialization of cell therapies with the world’s most innovative scientists and science, they will be able to bring the promise of cell therapy to life for more patients.

Chimeric Therapeutics has licensed the exclusive global rights to intellectual property covering the CLTX CAR T cell therapy which is currently in development for patients with progressive and recurrent glioblastoma and is also being investigated for development in patients with other solid tumors such as melanoma, small cell lung cancer, prostate cancer and colorectal cancer.

Chimeric Therapeutics is also currently actively engaged in enhancing their pipeline with other innovative cell therapies for patients with cancer.

## **CONTACT**

### Investors

Jennifer Chow  
Chief Operating Officer  
P: 908-723-8387  
E: [jchow@chimerictherapeutics.com](mailto:jchow@chimerictherapeutics.com)

### Media

Matthew Wright  
NWR Communications  
P: +61 451 896 420  
E: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)